Exelixis Inc

Financials

Activos totales 2.62 B3.07 B2.94 B2.95 B2.84 B Total de pasivos 405.62 M583.06 M678.45 M703.49 M683.1 M Capital total 2.21 B2.49 B2.26 B2.24 B2.16 B Total de pasivos y patrimonio neto 2.62 B3.07 B2.94 B2.95 B2.84 B Deuda total ————— Deuda neta —————

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

EXEL

Financials

Exelixis Inc

Noticias

Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound?

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis, Inc. (EXEL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Exelixis en Barclays Healthcare: crecimiento estratégico e información sobre su cartera

Exelixis en Barclays Salud: Crecimiento Estratégico y Perspectivas

Exelixis at Barclays Healthcare: Strategic Growth and Pipeline Insights

Exelixis en la Conferencia Global de Salud de Leerink: Perspectivas estratégicas en CCR y CCR

Exelixis en Conferencia Global de Salud Leerink: Perspectivas en RCC y CRC

Exelixis at Leerink Global Healthcare Conference: Strategic Insights in RCC and CRC

Exelixis, Inc. (EXEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Exelixis en TD Cowen: Visión estratégica y crecimiento

Exelixis at TD Cowen: Strategic Vision and Growth